Journal
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 24, Issue 1, Pages 31-36Publisher
AMER SOC NEPHROLOGY
DOI: 10.1681/ASN.2012040355
Keywords
-
Categories
Funding
- Encysive Pharmaceuticals
- Pfizer
- British Heart Foundation [PG/05/91]
- NHS Endowments
Ask authors/readers for more resources
Arterial stiffness and impaired nitric oxide (NO) bioavailability contribute to the high risk for cardiovascular disease in CKD. Both asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO production, and endothelin-1 (ET-1) oppose the actions of NO, suggesting that ET-1 receptor antagonists may have a role in cardiovascular protection in CKD. We conducted a randomized, double-blind, three-way crossover study in 27 patients with proteinuric CKD to compare the effects of the ETA receptor antagonist sitaxentan, nifedipine, and placebo on proteinuria, BP, arterial stiffness, and various cardiovascular biomarkers. After 6 weeks of treatment, placebo and nifedipine did not affect plasma urate, ADMA, or urine ET-1/creatinine, which reflects renal ET-1 production; in contrast, sitaxentan led to statistically significant reductions in all three of these biomarkers. No treatment affected plasma ET-1. Reductions in proteinuria and BP after sitaxentan treatment was associated with increases in urine ET-1/creatinine, whereas reduction in pulse-wave velocity, a measure of arterial stiffness, was associated with a decrease in ADMA. Taken together, these data suggest that ETA receptor antagonism may modify risk factors for cardiovascular disease in CKD. J Am Soc Nephrol 24: 31-36, 2013. doi: 10.1681/ASN.2012040355
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available